[Roncoleukin in enhancing the efficiency of complex therapy for infiltrative pulmonary tuberculosis in adolescents].
Seventy-eight patients, aged 15.69 +/- 0.15 years, who had infiltrative pulmonary tuberculosis, were examined. Roncoleukin was given intravenously in 20 patients of them (Subgroup 1a), in an indirect lymphotropic fashion in 30 patients (Subgroup 1b); 28 adolescents were treated with the conventional treatments (Group 2). A decay phase was recorded in 33 (66%) from Group 1 and in 16 (57.1%) from Group 2. On admission, all 78 (100%) patients had immunological disorders that required immunomodulation. Roncoleukin caused positive clinical and X-ray changes that were more pronounced in Subgroup 1b: bacterial excretion cessation was recorded in 100% of patients in Subgroup 1a (p < 0.05); in 94.4% in Subgroup 1b (p < 0.05), and in 68.7% in Group 2; decay cavities closed in 69.2, 60, and 37.5% in Subgroups 1a and 1b and Group 2. At the same time, the duration of a procedure considerably reduced, which positively affected adolescents' compliance.
Barmina
N A
NA
Burukhina
L V
LV
Shurygin
A A
AA
Archakova
L I
LI
D000293:Adolescent; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D007378:Interleukins / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
D000995:Antitubercular Agents; D007378:Interleukins; D011994:Recombinant Proteins